发明名称 Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
摘要 Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
申请公布号 US9255927(B2) 申请公布日期 2016.02.09
申请号 US201214115825 申请日期 2012.05.07
申请人 DUKE UNIVERSITY 发明人 Nixon Andrew B.;Hurwitz Herbert I.;Pang Herbert;Starr Mark D.
分类号 G01N33/574;G01N33/74;A61K39/395;C12Q1/68;C07K16/22;A61K31/7068;A61K39/00 主分类号 G01N33/574
代理机构 Andrus Intellectual Property Law, LLP 代理人 Andrus Intellectual Property Law, LLP
主权项 1. A method of predicting responsiveness of pancreatic cancer in a subject to a cancer therapy including a VEGF targeting agent comprising: obtaining a sample from the subject; measuring an protein expression level of at least one biomarker selected from Ang-2, SDF-1 and VEGF-D in the sample from the subject; and treating the subject with a VEGF targeting agent if the expression level of Ang-2 is greater than 305 pg/mL, the expression level of SDF-1 is more than 1100 pg/mL, or the expression level of VEGF-D is less than 1100 pg/mL.
地址 Durham NC US
您可能感兴趣的专利